These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27350147)

  • 1. Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity.
    Aubry AF; Dean B; Diczfalusy U; Goodenough A; Iffland A; McLeod J; Weng N; Yang Z
    AAPS J; 2016 Sep; 18(5):1056-1066. PubMed ID: 27350147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.
    Nitta SI; Hashimoto M; Kazuki Y; Takehara S; Suzuki H; Oshimura M; Akita H; Chiba K; Kobayashi K
    AAPS J; 2018 Apr; 20(3):61. PubMed ID: 29858698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS.
    Huang MQ; Lin W; Wang W; Zhang W; Lin ZJ; Weng N
    Biomed Chromatogr; 2014 Jun; 28(6):794-801. PubMed ID: 24861746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping.
    Suzuki Y; Oda A; Negami J; Toyama D; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K
    J Lipid Res; 2022 Mar; 63(3):100184. PubMed ID: 35181316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.
    Mao J; Martin I; McLeod J; Nolan G; van Horn R; Vourvahis M; Lin YS
    Drug Metab Rev; 2017 Feb; 49(1):18-34. PubMed ID: 27718639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid LC-MS/MS method for the determination of 4-hydroxycholesterol/cholesterol ratio in serum as endogenous biomarker for CYP3A activity in human and foals.
    Hasan M; Siegmund W; Oswald S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1033-1034():193-199. PubMed ID: 27565568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume.
    Xu Y; Yuan Y; Smith L; Edom R; Weng N; Mamidi R; Silva J; Evans DC; Lim HK
    J Pharm Biomed Anal; 2013 Nov; 85():145-54. PubMed ID: 23948760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
    Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H
    Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity.
    Taya Y; Mizunaga M; Nakao S; Jutanom M; Shimizu N; Nomura Y; Nakagawa K
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy.
    Wide K; Larsson H; Bertilsson L; Diczfalusy U
    Br J Clin Pharmacol; 2008 May; 65(5):708-15. PubMed ID: 18279471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.
    Diczfalusy U; Kanebratt KP; Bredberg E; Andersson TB; Böttiger Y; Bertilsson L
    Br J Clin Pharmacol; 2009 Jan; 67(1):38-43. PubMed ID: 19006545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formation of CYP3A-specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β-hydroxycholesterol/cholesterol ratio.
    Lee J; Fallon JK; Smith PC; Jackson KD
    Clin Transl Sci; 2023 Feb; 16(2):279-291. PubMed ID: 36350327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasma.
    van de Merbel NC; Bronsema KJ; van Hout MW; Nilsson R; Sillén H
    J Pharm Biomed Anal; 2011 Jul; 55(5):1089-95. PubMed ID: 21507593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.
    Gebeyehu E; Engidawork E; Bijnsdorp A; Aminy A; Diczfalusy U; Aklillu E
    Pharmacogenomics J; 2011 Apr; 11(2):130-7. PubMed ID: 20231858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1β-Hydroxydeoxycholic Acid as an Endogenous Biomarker in Human Plasma for Assessment of CYP3A Clinical Drug-Drug Interaction Potential.
    Xue Y; Wang L; Huo R; Chen M; Melo B; Dingley K; Gaudy A; Shen JX
    Drug Metab Dispos; 2024 Aug; 52(9):966-974. PubMed ID: 38991779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of induced CYP3A activity in pregnant women using 4β-hydroxycholesterol: Cholesterol ratio as an appropriate metabolic marker.
    Kim AH; Kim B; Rhee SJ; Lee Y; Park JS; Lee SM; Kim SM; Lee S; Yu KS; Jang IJ; Cho JY
    Drug Metab Pharmacokinet; 2018 Jun; 33(3):173-178. PubMed ID: 29759884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the usefulness of plasma 4β-hydroxycholesterol concentration normalized by 4α-hydroxycholesterol for accurate CYP3A phenotyping.
    Oda A; Suzuki Y; Sato H; Koyama T; Nakatochi M; Momozawa Y; Tanaka R; Ono H; Tatsuta R; Ando T; Shin T; Wakai K; Matsuo K; Itoh H; Ohno K
    Clin Transl Sci; 2024 Mar; 17(3):e13768. PubMed ID: 38465776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction.
    Xue YJ; Hoffmann M; Tong Z; Wu XI; Vallejo M; Melo B; Ye Y; Thomas M; Liu Y; Weiss D; Surapaneni S
    Bioanalysis; 2016 Feb; 8(3):215-28. PubMed ID: 26805594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
    Josephson F; Bertilsson L; Böttiger Y; Flamholc L; Gisslén M; Ormaasen V; Sönnerborg A; Diczfalusy U
    Eur J Clin Pharmacol; 2008 Aug; 64(8):775-81. PubMed ID: 18458892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.
    Penzak SR; Rojas-Fernandez C
    J Clin Pharmacol; 2019 May; 59(5):611-624. PubMed ID: 30748026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.